Federica Fogacci, Young Fellow at European Atherosclerosis Society, shared on X:
“PCSK9 pharmacology is getting crowded (in the best possible way).
In CORALreef AddOn, oral enlicitide reduced LDL-C, ApoB and non-HDL-C vs oral non-statin comparators.
Soon at EAS Congress 2026, Prof. Alberico L. Catapano focuses on ApoB in phase 3 trials.”
Title: Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial
Authors: Alberico L. Catapano, Elina Mikhailova, Ann Marie Navar, Puja Banka, Pablo Corral, Manish Saxena, P. Gabriel Steg, Subodh Verma, Andrew Yacoub Kordahi, Geraldine Mendizabal, Pengfei Zhu, Christie M. Ballantyne
Other articles on OncoDaily.